Further Synthesis of Enkephalinol Analogs containing the Dipeptide Unit Tyr-Arg (Kyotorphin)\(^1\)

**Minoru Kubota,\(^*,\) Hiroshi Kojima,\(^*\) Osamu Nagase,\(^*\) Hiro Amano,\(^*\) Hiroshi Takagi,\(^*\) and Haruaki Yajima\(^*\)**

*Research Institute, Daiichi Seiyaku Co., Ltd.\(^*\), Kitakasai, Edogawa-ku, Tokyo, 134, Japan and Faculty of Pharmaceutical Sciences, Kyoto University,\(^*\)
Sakyo-ku, Kyoto, 606, Japan*

(Received January 28, 1982)

In order to obtain enkephalin derivatives with high analgesic activity, four enkephalinol analogs having the Tyr-d-Arg unit in the N-terminal position were synthesized. Of these, H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol exhibited analgesic activity comparable to that of morphine after intravenous administration to mice.

**Keywords**——enkephalinol; kyotorphin; methanesulfonic acid deprotection; sodium borohydride reduction; analgesic effect

Previously, we synthesized eight Met- and Leu-enkephalin analogs containing the dipeptide unit, Tyr-Arg (kyotorphin).\(^2\) Of these, H-Tyr-d-Arg-Gly-Phe-Met-OH was found to possess an analgesic effect 2.4 times higher than that of morphine on a molar basis, when injected intracisternally. This compound was also found to produce analgesia when administered intravenously. Recently, it has been reported that some C-terminal amino alcohol derivatives, such as H-Tyr-d-Ala-Gly-MePhe-Met(O)-ol\(^3\) and H-Tyr-d-Met(O)-Gly-MePhe-ol,\(^4\) were found to be several times more analgesic than morphine in experimental animals after s.c. administration.

We have therefore synthesized four peptides: H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol, Me-Tyr-d-Arg-Gly-MePhe-Met(O)-ol, H-Tyr-d-Arg-Gly-MePhe-Leu-ol and H-Tyr-d-Arg-Gly-MePhe-Ile-ol, using readily available a-amino alcohols.\(^5,\)\(^6\)

The first compound, H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol, was synthesized starting with Z(OMe)-Met-ol\(^6\) prepared by the reduction of Z(OMe)-Met-OPCP with NaBH\(_4\). This, after removal of the Z(OMe) group with TFA,\(^7\) was condensed successively with Z(OMe)-MePhe-OH and Boc-Gly-OH by the mixed anhydride procedure as shown in Fig. 1.

Attempts to crystallize Boc-Gly-MePhe-Met-ol have been unsuccessful. This peptide was oxidized to the corresponding sulfoxide, Boc-Gly-MePhe-Met(O)-ol, by sodium metaperi-

![Synthetic Scheme for [d-Arg\(^8\), MePhe\(^4\), Met(O)\(^4\)]enkephalinol](image)

Fig. 1. Synthetic Scheme for [d-Arg\(^8\), MePhe\(^4\), Met(O)\(^4\)]enkephalinol
The Boc group was removed from the resulting powder by TFA treatment as usual and the resulting peptide was condensed with Z-Tyr-\(\alpha\)-Arg(Mts)-NHNH\(_2\)\(^{40}\) by Rudinger’s azide procedure.\(^{40}\) Z and Mts\(^ {10}\) were removed from the resulting protected peptide by MSA treatment.\(^ {11}\) In order to suppress a possible side reaction at the Tyr residue, \(i.e.,\), O-mesitylene sulfonylation,\(^ {8}\) a mixture of scavengers, thioanisole-\(\alpha\)-cresol, was employed. The deblocked peptide was converted to the corresponding acetate by treatment with Dowex 1 (acetate form) and purified by gel-filtration on Sephadex G-15, followed by column chromatography on carboxymethyl (CM)-cellulose. In the latter step, gradient elution was employed to elute the desired compound with ammonium acetate buffers. After lyophilization, homogeneity of the product was ascertained by thin layer chromatography (TLC) acid hydrolysis and elemental analysis.

The second compound, Me-Tyr-\(\alpha\)-Arg-Gly-MePhe-Met(O)-ol, was synthesized starting with H-Gly-MePhe-Met(O)-ol (Fig. 2). This tripeptide was condensed successively with Z(OMe)-\(\alpha\)-Arg(Mts)-OH and Boc-MeTyr(Bzl)-OH\(^ {12}\) by the DCC-HOSu\(^ {13}\) and the TCP\(^ {14}\) ester procedures, respectively. Deprotection and purification of the resulting protected peptide, Boc-MeTyr-\(\alpha\)-Arg(Mts)-Gly-MePhe-Met(O)-ol, were performed in essentially the same manner as mentioned above.

![Fig. 2. Synthetic Scheme for Me-Tyr-\(\alpha\)-Arg-Gly-MePhe-Met(O)-ol](image)

The third compound H-Tyr-\(\alpha\)-Arg-Gly-MePhe-Leu-ol was synthesized starting with Z(OMe)-Leu-ol prepared by the reduction of the corresponding active ester of Z(OMe)-Leu-\(\text{OH}\) with NaBH\(_4\) (Fig. 3). Z(OMe)-Leu-ol, after removal of the Z(OMe) group with TFA, was condensed with Z(OMe)-MePhe-\(\text{OH}\) by the mixed anhydride procedure. The resulting peptide, Z(OMe)-MePhe-Leu-ol, was obtained as an oily compound, from which the Z(OMe) group was cleaved with HCl-dioxane to afford the hydrochloride as a crystalline compound. The N-

![Fig. 3. Synthetic Scheme for H-Tyr-\(\alpha\)-Arg-Gly-MePhe-X-ol (X=Leu or Ile)](image)
terminal tripeptide, Z-Tyr-d-Arg(Mts)-Gly-OH, was prepared by the 2+1 coupling method, i.e., the azide condensation of Z-Tyr-d-Arg(Mts)-NHNH₂ with the triethylammonium salt of H-Gly-OH, and then condensed with H-MePhe-Leu-ol obtained above by the DCC-HOBt procedure to afford Z-Tyr-d-Arg(Mts)-Gly-MePhe-Leu-ol. The corresponding Ile-ol compound, Z-Tyr-d-Arg(Mts)-Gly-MePhe-Ile-ol, was similarly prepared. The deprotection and purification of these two enkephalinologals were performed in essentially the same manner as described above.

The analgesic effects of these four synthetic enkephalin analogs are listed in Table I. In terms of the tail-flick test, H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol exhibited analgesic activity comparable to that of morphine when administered intravenously. However, the corresponding N-methylated compound MeTyr-d-Arg-Gly-MePhe-Met(O)-ol, was less active. The corresponding Leu-ol, and Ile-ol compounds were also less active. H-Tyr-d-Arg-Gly-MePhe-Leu-ol seems to be toxic. After intravenous administration, all of the mice tested (5) died of respiratory collapse within a few minutes.

<table>
<thead>
<tr>
<th>Compound</th>
<th>ED₅₀ (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol</td>
<td>0.62(0.31—1.22)</td>
</tr>
<tr>
<td>Me-Tyr-d-Arg-Gly-MePhe-Met(O)-ol</td>
<td>2.8 (1.4 —5.8)</td>
</tr>
<tr>
<td>H-Tyr-d-Arg-Gly-MePhe-Leu-ol</td>
<td>≥10</td>
</tr>
<tr>
<td>H-Tyr-d-Arg-Gly-MePhe-Ile-ol</td>
<td>≥20</td>
</tr>
<tr>
<td>Morphine</td>
<td>0.85(0.56—1.28)</td>
</tr>
</tbody>
</table>

(tail-flick method)

The analgesic effect of H-Tyr-d-Arg-Gly-MePhe-Met(O)-ol was also evaluated by the tail-pinch method. The ED₅₀ value of this peptide (5.2 mg/kg) was comparable to that of morphine (4.0 mg/kg) in the mouse after intravenous administration.

**Experimental**

General experimental procedures were essentially the same as those described in the previous paper. Thin layer chromatography was performed on silica gel (Kieselgel G, Merck). Rf values refer to the following solvent systems: Rf₁ CHCl₃-MeOH-H₂O (8:3:1), Rf₂ CHCl₃-MeOH-AcOH (95:5:3), Rf₃ n-BuOH-AcOH-AcOEt-H₂O (1:1:1:1).

Z(OMe)-MePhe-OH-DCHA — CH₄I (5 ml) and NaH (1.32 g, 55 mmol) were added to a solution of Z(OMe)-Phe-OH (3.29 g, 10 mmol) in THF (50 ml) under ice cooling. The mixture was stirred at room temperature for 4 h, then the solvent was removed by evaporation and the residue was dissolved in H₂O. This solution was washed with AcOEt, and acidified with citric acid. The resulting precipitate was extracted with AcOEt. The extract was washed with 5% Na₂SO₄ and H₂O—NaCl, dried over Na₂SO₄ and concentrated. The residue was dissolved in ether (20 ml) and dicyclohexylamine (2 ml, 10 mmol) was added. The solvent was evaporated off and the residue was triturated with petroleum ether. The resulting solid was recrystallized from AcOEt and petroleum ether; yield 4.37 g (90%), mp 100—102°C, [x]D = 18.0° (c = 0.3, MeOH), Rf₂ 0.34. Anal. Calcd for C₃₈H₄₁N₂O₄: C, 70.96; H, 8.45; N, 5.54. Found: C, 70.94; H, 8.42; N, 5.30.

Z(OMe)-MePhe-Met-ol — Z(OMe)-Met-ol (2.28 g, 7.63 mmol) was treated with TFA—anisole (6 ml—4 ml) in an ice-bath for 60 min, then petroleum ether was added. The resulting oily precipitate was washed with petroleum ether, dried over KOH pellets in vacuo and then dissolved in THF (5 ml) containing Et₃N (1.06 ml, 7.63 mmol). The mixed anhydride [prepared from 4.00 g, (7.63 mmol) of Z(OMe)-MePhe-OH-DCHA as usual] in THF (10 ml) was added to the above ice-chilled solution and the mixture was stirred in an ice-bath for 2 h and then for an additional 3 h at room temperature. The solvent was evaporated off and the residue was dissolved in AcOEt. This solution was washed with 0.1 N HCl, 5% NaHCO₃ and H₂O—NaCl, dried over Na₂SO₄ and then concentrated to give an oily product. Rf₁ 0.77. Attempts to solidify this compound have been unsuccessful. yield 3.34 g (95%).

HCl—H-MePhe-Met-ol — Z(OMe)-MePhe-Met-ol (4.61 g, 10 mmol) dissolved in THF (5 ml) was treated with 6.2 N HCl—THF (20 ml) in the presence of dimethylsulphide (3 ml) for 1 h. The product was precipitated...
by addition of dry ether, and then recrystallized from EtOH and ether; yield 2.67 g (80%), mp 152–154°C, [α]D +14.4° (c=0.2 MeOH) (lit.3+ 12.6 in MeOH). RfI 0.61. Anal. Caled for C44H36N2O9S2Cl-1/4H2O: C, 53.40; H, 7.62; N, 8.30. Found: C, 53.67; H, 7.44; N, 8.04.

**Boc-Gly-MePh-Met-ol**—In the usual manner, a mixed anhydride [prepared from 1.04 g, (8 mmol) of Boc-Gly-OH] in THF (10 ml) was added to a solution of HCl-H-MePh-Met-ol (2.66 g, 8 mmol) and Et2N (1.12 ml, 8 mmol) in DMF (15 ml). After being stirred at 0°C for 2 h and then at room temperature for 3 h, the solution was concentrated, and the residue was dissolved in AcOEt. This solution was washed with 0.1 n HCl, 5% NaHCO3 and H2O-NaCl, dried over Na2SO4 and then concentrated to give an oily residue. RfI 0.63, yield 3.60 g (90%).

**Boc-Gly-MePh-Met-O(0)-ol**—To a solution of Boc-Gly-MePh-Met-ol (3.60 g, 7.9 mmol) in MeOH (40 ml), NaOEt (1.71 g, 8 mmol) in H2O (40 ml) was added. After being stirred at room temperature for 3 h, the solution was filtered. The filtrate was concentrated and the residue was dissolved in AcOEt. This solution was washed with 0.1 n HCl, 5% NaHCO3 and H2O-NaCl, dried over Na2SO4 and then evaporated to dryness. The residue was triturated with n-hexane; yield 3.63 g (98%), mp 74–78°C, [α]D +54.2° (c=0.2, MeOH). RfI 0.39. Anal. Caled for C26H35N2O7S: C, 56.27; H, 7.51; N, 8.95. Found: C, 56.29; H, 7.40; N, 8.29.

**HCL H-Gly-MePh-Met-O(0)-al**—A solution of Boc-Gly-MePh-Met-O(0)-ol (2.58 g, 5.4 mmol) in THF (10 ml) was treated with 6.2 n HCl-THF (20 ml), and the mixture was stirred at room temperature for 1 h. After addition of ether, the resulting powder was collected by filtration and recrystallized from EtOH and ether; yield 1.87 g (84%), mp 95–99°C, [α]D +46.5° (c=0.4, MeOH) RfI 0.29. Anal. Caled for C14H20N3O5S·HCl·1/2H2O: C, 49.20; H, 7.04; N, 10.13. Found: C, 48.84; H, 7.21; N, 9.71.

**Z-Tyr-d-Arg(Mts)-Gly-MePh-Met-O(0)-ol**—HCl-H-Gly-MePh-Met-O(0)-ol (0.81 g, 2 mmol) was dissolved in DMF (5 ml) containing Et2N (0.28 ml, 2 mmol). To this ice-chilled solution, the azide (prepared from 1.34 g, (2 mmol) of Z-Tyr-d-Arg(Mts)-NHNH2) in DMF (5 ml) and Et2N (0.28 ml, 2 mmol) were added. After being stirred at 4°C for 48 h, the solution was concentrated and the residue was treated with ether. The resulting powder was washed with 0.2 n AcOEt and H2O and precipitated from DMF with ether, yield 1.54 g (77%), mp 145–150°C, [α]D +22.1° (c=0.4, MeOH). RfI 0.44. Anal. Caled for C40H44N11O13S·H2O: C, 57.51; H, 6.50; N, 10.95. Found: C, 57.72; H, 6.20; N, 10.65.

**H-Tyr-d-Arg-Gly-MePh-Met-O(0)-ol**—The above protected peptide (502 mg, 0.5 mmol) was treated with NaOH-TFA (3 ml, 1 ml) in the presence of thioanisole-o-cresol (1:1, v/v, 1 ml) in an ice-bath for 15 min and at room temperature for 60 min, then dry ether was added. The resulting oily precipitate was washed with ether, dissolved in H2O (10 ml) and treated with Dowex 1 (acetate form, approximately 3 g) for 30 min. The resin was removed by filtration, and the filtrate was lyopholized. The residue was subjected to gel-filtration on Sephadex G-15 (3 x 110 cm), which was eluted with 0.2 n AcOEt. Individual fractions (5 ml each) were collected and the ultraviolet (UV) absorption at 275 nm was determined. The desired fractions (tube Nos. 65–104) were combined and the solvent was removed by lyopholization. The resulting powder was dissolved in H2O (30 ml) and applied to a column of CM-cellulose (1.8 x 50 cm), which was first eluted with H2O (300 ml) and then with a gradient formed from 0.5 M NH4OAc (pH 6.9, 1000 ml) through a mixing flask containing H2O (1000 ml). Individual fractions (10 ml each) were collected and the UV absorption at 275 nm was determined. The desired fractions (tube Nos. 52–74) were combined and the solvent was removed by lyopholization. For desalting, the product was dissolved in 0.2 n AcOH and the solution was applied to a column of Sephadex G-15 (3 x 110 cm), which was eluted with the same solvent. Individual fractions (5 ml each) were collected and the desired fractions (tube Nos. 73–86) were collected in essentially the same manner as described above. Lyopholization gave a white fluffy powder; yield 150 mg (37%), [α]D +12.9° (c=0.6, 0.2 n AcOH), RfI 0.58, RfI 0.60. Amino acid ratios in 3 n Tos-OH hydrolysat: Tyr 0.95, Arg 0.98, Gly 1.00 (average recovery 89%). Anal. Caled for C41H42N11O13S·2CH2COOH·2H2O·C, 50.63; H, 7.20; N, 13.12. Found: C, 50.67; H, 6.82; N, 12.60.

**Boc-MeTyr(Bz)-OTCP**—CH3I (17 ml, 0.27 mmol) and NaH (4.35 g, 0.18 mol) were added to a solution of Boc-Tyr(Bz)-OH in THF (90 ml) under ice cooling. The mixture was stirred at room temperature for 18 h, then the solvent was evaporated off and the residue was dissolved in H2O. The aqueous phase was washed with AcOEt and then acidified with citric acid. The resulting precipitate was extracted with AcOEt. The extract was washed with 5% Na2SO4 and H2O-NaCl, dried over Na2SO4 and concentrated. The residue was dissolved in THF (50 ml) and then HOTCP (6.58 g, 33 mmol) and DCC (6.87 g, 33 mmol) were added. After being stirred at room temperature for 18 h, the solution was filtered and the filtrate was concentrated. The residue was triturated with n-hexane and recrystallized from n-hexane; yield 16.58 g (88%), mp 71–73°C, [α]D +58.7° (c=0.3, MeOH). RfI 0.92. Anal. Caled for C42H39N11O13N2OCl-2H2O: C, 59.53; H, 4.99; N, 2.48. Found: C, 59.92; H, 5.08; N, 2.54.

**Z(OMe)-d-Arg(Mts)-Gly-MePh-Met-O(0)-ol**—HOSu (130 mg, 1.13 mmol), HCl-H-Gly-MePh-Met-O(0)-ol (459 mg, 1.13 mmol), and Et2N (0.16 ml, 1.13 mmol) were added to a solution of Z(OMe)-d-Arg(Mts)-OH [prepared from 700 mg, (1.13 mmol) of the DCHA salt as usual] in THF (3 ml). To this mixture, DCC (233 mg, 1.13 mmol) was added and the whole was stirred at room temperature for 18 h. The solution was filtered, and the filtrate was concentrated. The residue was dissolved in AcOEt. This solution was washed with 0.1 n HCl, 5% NaHCO3 and H2O-NaCl, dried over Na2SO4 and then concentrated. The residue was
triturated with ether and precipitated with THF and ether; yield 650 mg (66%), mp 108—112°C, $\left[x\right]_D^{25} = -23.8^\circ$ (c = 0.3, MeOH). $R_f$ 0.54. *Anal.* Calcd for C$_{43}$H$_{44}$N$_{3}$O$_7$S$_2$: 1.5H$_2$O: C, 54.77; H, 6.73; N, 10.91. Found: C, 54.65; H, 6.33; N, 10.75.

**Boc-MeTyr(Bzl)-d-Arg(Mts)-Gly-MePhe-Met(O)-ol**——In the usual manner, Z(OMe)-d-Arg(Mts)-Gly-MePhe-Met(O)-ol (523 mg, 0.6 mmol) was treated with TFA-anisole (0.8 ml–0.3 ml) at 0°C for 1 h, then dry ether was added. The resulting powder was dissolved in DMF (3 ml), together with Boc-MeTyr(Bzl)-OTCP (339 mg, 0.6 mmol), HOBT (81 ml, 0.6 mmol) and Et$_3$N (0.17 ml, 1.2 mmol). After being stirred at room temperature for 24 h, the solution was concentrated and the residue was triturated with ether. The resulting powder was recrystallized from EtOH and ether. Yield 477 mg (74%), mp 119—123°C, $\left[x\right]_D^{25} = -36.9^\circ$ (c = 0.3, MeOH). $R_f$ 0.61. *Anal.* Calcd for C$_{44}$H$_{44}$N$_{3}$O$_7$S$_2$: 1.5H$_2$O: C, 59.32; H, 7.01; N, 10.25. Found: C, 59.51; H, 6.68; N, 10.76.

**Me-Tyr-d-Arg-Gly-MePhe-Met(O)-ol**——The above protected peptide (323 mg, 0.3 mmol) was treated with MSA–TFA (2 ml–0.5 ml) in the presence of thioanisole (0.3 ml) and o- cresol (0.3 ml) in an ice-bath for 15 min and at room temperature for 1 h. The deprotected peptide was converted to the corresponding acetate, and purified by column chromatography on Sephadex G-15 followed by CM-cellulose as described for the purification of H-Tyr-d-Arg—Gly—MePhe—Met(O)—ol; yield 83 mg (52%), $\left[x\right]_D^{33} = +33.7^\circ$ (c = 0.1, 0.2 N AcOH). $R_f$ 0.67. *Anal.* Calcd for C$_{23}$H$_{22}$N$_{3}$O$_7$: 1.5H$_2$O: C, 53.28; H, 7.28; N, 14.20. Found: C, 53.59; H, 6.84; N, 14.51.

**Z-Tyr-d-Arg(Mts)-Gly—OH**——To a solution of H—Gly—OH (338 mg, 4.5 mmol) in H$_2$O (3 ml) containing Et$_3$N (0.63 ml, 4.5 mmol), the azide [prepared from 2.00 g, (3 mmol) of Z-Tyr-d-Arg(Mts)—NH$_2$H$_2$] in DMF (4 ml) and Et$_3$N (0.42 ml, 3 mmol) were added. After being stirred at 4°C for 48 h, the solution was concentrated and the residue was treated with 0.2 N AcOH and ether. The resulting powder was recrystallized from MeOH and ether; yield 1.87 g (88%), mp 125—130°C, $\left[x\right]_D^{25} = +16.9^\circ$ (c = 0.4, MeOH). $R_f$ 0.23. *Anal.* Calcd for C$_{42}$H$_{42}$N$_{7}$O$_7$: H$_2$O: C, 56.03; H, 6.09; N, 11.53. Found: C, 56.33; H, 6.46; N, 11.22.

**HCl—H-MePhe-Leu—ol**——Z(OMe)—Leu—ol (0.84 g, 3 mmol) was treated with TFA-anisole (2.3 ml–1.6 ml) as usual and $n$-hexane was added. The precipitate was washed with $n$-hexane, dried over KOH pellets in vacuo for 3 h and dissolved in THF (4 ml) containing Et$_3$N (0.35 ml). To this ice-chilled solution, the mixed anhydride [prepared from 1.31 g, (2.5 mmol) of the DCHA salt of Z(OMe)—MePhe—OH] in THF (4 ml) was added and the mixture was stirred in an ice-bath for 1 h then at room temperature for 3 h. The solvent was evaporated off and the residue was dissolved in AcOEt. This solution was washed with 0.1 N HCl, 5% NaHCO$_3$ and H$_2$O—NaCl, dried over Na$_2$SO$_4$ and concentrated. The oily residue was treated with 2.5 N HCl—dioxane in the presence of anisole (1.5 ml) at room temperature for 1 h. Ether was added and the resulting powder was recrystallized from EtOH and ether; yield 0.40 g (51%), mp 207—210°C, $\left[x\right]_D^{25} = +10.0^\circ$ (c = 0.2, MeOH). $R_f$ 0.54. *Anal.* Calcd for C$_{16}$H$_{17}$N$_{2}$O$_7$: C, 61.03; H, 8.64; N, 8.90. Found: C, 60.88; H, 8.47; N, 8.79.

**Z-Tyr-d-Arg(Mts)—Gly—MePhe—Leu—ol**——DCD (165 mg, 0.8 mmol) was added to a mixture of Z-Tyr—d-Arg(Mts)—Gly—OH (569 mg, 0.8 mmol), HOBT (108 mg, 0.8 mmol), HCl—H—MePhe—Leu—ol (255 mg, 0.8 mmol) and Et$_3$N (0.11 ml, 0.8 mmol) in DMF (2 ml) and the mixture, after being stirred at room temperature for 24 h, was filtered. The filtrate was concentrated and the residue was dissolved in AcOEt. This solution was washed with 1 N HCl, 5% NaHCO$_3$ and H$_2$O—NaCl, dried over Na$_2$SO$_4$ and then concentrated. Trituration of the residue with ether afforded a powder; yield 560 mg (72%), mp 132—136°C, $\left[x\right]_D^{25} = +3.0^\circ$ (c = 0.3, MeOH), $R_f$ 0.61. *Anal.* Calcd for C$_{42}$H$_{42}$N$_{7}$O$_7$: 1.5H$_2$O: C, 60.16; H, 6.97; N, 11.23. Found: C, 60.30; H, 6.90; N, 11.50.

**H-Tyr—d-Arg—Gly—MePhe—Leu—ol**——The above protected peptide (286 mg, 0.29 mmol) was treated with MSA–TFA (3 ml–1 ml) in the presence of thioanisole (1 ml) in an ice-bath for 15 min and at room temperature for 1 h. The deprotected peptide was converted to the corresponding acetate and purified by gel filtration on Sephadex G-15, followed by column chromatography on CM-cellulose as described above; yield 95 mg (50%), $\left[x\right]_D^{25} = +25.2^\circ$ (c = 0.3, 0.2 N AcOH). $R_f$ 0.63. Amino acid ratios in 3 N Tos-OH hydrolysate; Tyr 0.97, Arg 1.04, Gly 1.00 (average recovery 87%). *Anal.* Calcd for C$_{33}$H$_{34}$N$_{16}$O$_{16}$: 2CH$_2$COOH: 4H$_2$O: C, 52.46; H, 7.85; N, 13.23. Found: C, 52.08; H, 7.91; N, 12.96.

**HCl—H-MePhe—Ile—ol**——Z(OMe)—Ile—ol (0.70 g, 2.5 mmol) was treated with TFA-anisole (2.3 ml–1.6 ml) as usual and $n$-hexane was added. The precipitate was washed with $n$-hexane, dried in vacuo and dissolved in THF (4 ml) containing Et$_3$N (0.35 ml, 2.5 mmol). To this ice-chilled solution, the mixed anhydride [prepared from 1.31 g, (2.5 mmol) of the DCHA salt of Z(OMe)—MePhe—OH as usual] in THF (4 ml) was added and the mixture was stirred in an ice-bath for 2 h then at room temperature for 18 h. The solvent was evaporated off and the residue was dissolved in AcOEt. This solution was washed with 0.1 N HCl, 5% NaHCO$_3$ and H$_2$O—NaCl, dried over Na$_2$SO$_4$ and concentrated. The oily residue was treated with 2.5 N HCl—dioxane in the presence of anisole (1.5 ml) as stated above. Ether was added and the resulting powder was recrystallized from EtOH and ether; yield 0.36 g (46%), mp 206—209°C, $\left[x\right]_D^{25} = +4.2^\circ$ (c = 0.5, MeOH), $R_f$ 0.54. *Anal.* Calcd for C$_{14}$H$_{14}$N$_{2}$O$_7$: 1.4H$_2$O: C, 60.17; H, 8.68; N, 8.77. Found: C, 60.36; H, 8.76; N, 8.53.

**Z-Tyr—d-Arg(Mts)—Gly—MePhe—Ile—ol**——DCC (165 mg, 0.8 mmol) was added to a mixture of Z-Tyr—d-Arg(Mts)—Gly—OH (668 mg, 0.8 mmol), HOBT (108 mg, 0.8 mmol), HCl—I—MePhe—Ile—ol (252 mg, 0.8 mmol)
and Et₃N (0.11 ml, 0.8 mmol) in DMF (4 ml) and the mixture, after being stirred at room temperature for 24 h, was filtered. The filtrate was concentrated and the residue was dissolved in AcOEt. This solution was washed with 1 x HCl, 5% NaHCO₃ and H₂O–NaCl, dried over Na₂SO₄ and then concentrated. Trituration of the residue with ether afforded a powder; yield 544 mg (70%), mp 130—135°C, [α]ₑ₂⁰ +4.8° (c=0.3, MeOH), Rf₁ 0.61. Anal. Calcd for C₃₅H₅₁N₂O₁₅S·H₂O: C, 60.72; H, 6.92; N, 11.33. Found: C, 60.55; H, 6.65; N, 11.29.

H-Tyr-p-Arg-Gly-Mphe-Ile-ol——The above protected peptide (191 mg, 0.2 mmol) was treated with MSA–TFA (2.5 ml–1 ml) in the presence of thioanisole–o-cresol (1: 1, v/v, 1 ml) in an ice-bath for 15 min and at room temperature for 1 h. The deprotected peptide was converted to the corresponding acetate and purified by gel filtration on Sephadex G-15, followed by column chromatography on CM-cellulose as described above; yield 64 mg (49%) [α]₁₂⁰ +34.2° (c=0.1, 0.2 N AcOH), Rf₂ 0.63. Amino acid ratios in 3 N Tos-OH hydrolysate: Tyr 0.93, Arg 0.97, Gly 1.00 (average recovery 85%). Anal. Calcd for C₂₅H₄₆N₄O₄·2CH₃COOH·2H₂O: C, 54.80; H, 7.71; N, 13.82. Found: C, 55.22; H, 7.30; N, 13.58.

Acknowledgement The authors are grateful to Dr. Yoshio Morita, the vice-director of the Research Institute, Daiichi Seiyaku Co., Ltd., for his encouragement throughout this work.

References and Notes

1) The following abbreviations are used: Z=benzoyloxy carbonyl, Z(OMe)=p-methoxybenzoyloxy carbonyl, HOBt=1-hydroxybenzotriazole HOSu= N-hydroxysuccinimide, MSA=methanesulfonic acid, DMF=dimethylformamide, THF=tetrahydrofuran, TFA=trifluoroacetic acid, Ms=mesitylene-2-sulfonyl, OPCI=pentachlorophenyl ester, OTCP=2,4,5-trichlorophenyl ester, DCHA=dicyclohexylamine, Met(O)-ol=methioninol sulfoxide, Leu-o-leucinol, Ile-o-isoleucinol.


